Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Zolgensma with a clinician who has prescribed the drug to a patient since launch, after recent news of data manipulation has come to surface

Ticker(s): NVS, BIIB

Who's the expert?

Name: Dr Farida Abid - MD

Institution: Baylor College of Medicine / Texas Children's Hospital

  • Specialist in neuromuscular disorders, with experience in multiple clinical trials focused on various Muscular Dystrophies.
  • Currently manages 36 patients with SMA.
  • Her center has administered Zolgensma to a patient since approval.

Interview Questions
Q1.

What is your initial experience using Zolgensma in patients?

Added By: joe_mccann
Q2.

How much have you followed the recent headlines on data manipulation? How has that impacted your view of Zolgensma?

Added By: joe_mccann
Q3.

What questions are parents asking about gene therapy?  How are you managing discussions with parents about the lack of long-term data on Zolgensma?

Added By: catherineb
Q4.

What convinces her that Risdiplam, Zolgensma and Spinraza have equivalent efficacy?

Added By: catherineb

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.